Remdesivir for Patients Hospitalized with COVID-19 Severe Pneumonia: A National Cohort Study (Remdeco-19) - Université Paris Cité Accéder directement au contenu
Article Dans Une Revue Journal of Clinical Medicine Année : 2022

Remdesivir for Patients Hospitalized with COVID-19 Severe Pneumonia: A National Cohort Study (Remdeco-19)

1 Hôpital Cochin [AP-HP]
2 CHRU Besançon - Centre Hospitalier Régional Universitaire de Besançon
3 AP-HP - Hopital Saint-Louis [AP-HP]
4 Biostatistique et épidemiologie clinique
5 IC UM3 (UMR 8104 / U1016) - Institut Cochin
6 ICAN - Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases
7 Institut de cardiologie [CHU Pitié-Salpêtrière]
8 AP-HP - Hôpital Bichat - Claude Bernard [Paris]
9 CHU Toulouse - Centre Hospitalier Universitaire de Toulouse
10 CPTP - Centre de Physiopathologie Toulouse Purpan
11 ToNIC - Toulouse NeuroImaging Center
12 Hôpital de Hautepierre [Strasbourg]
13 HUS - Les Hôpitaux Universitaires de Strasbourg
14 Hôpital Raymond Poincaré (Garches) [GHU AP-HP Université Paris-Saclay]
15 2I - Infection et inflammation
16 CHU Dijon
17 Groupe Hospitalier Intercommunal Le Raincy-Montfermeil
18 CHU Nantes - Centre Hospitalier Universitaire de Nantes
19 CHU - BREST - Hôpital de la Cavale Blanche - CHRU Brest
20 CHU Clermont-Ferrand
21 Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois]
22 CHU Montpellier
23 Hôpital Pellegrin
24 Hôpital Louis Mourier - AP-HP [Colombes]
25 Hôpitaux Civils de Colmar
26 CHUGA - Centre Hospitalier Universitaire [CHU Grenoble]
27 Service des Maladies Infectieuses et Tropicales [CHRU Nancy]
28 CHRO - Centre Hospitalier Régional d'Orléans
29 Centre Hospitalier Sud Francilien
30 Centre hospitalier d'Ajaccio
31 RIGHT - Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098)
Amelie Cransac
Pascal Andreu
  • Fonction : Auteur
Marie Labruyère
  • Fonction : Auteur
Jean-François Huon
Lise Bernard
Maxime Villiet
  • Fonction : Auteur
Arnaud Venet
  • Fonction : Auteur

Résumé

Background. Given the rapidly evolving pandemic of COVID-19 in 2020, authorities focused on the repurposing of available drugs to develop timely and cost-effective therapeutic strategies. Evidence suggested the potential utility of remdesivir in the framework of an early access program. REMDECO-19 is a multicenter national cohort study assessing the ability of remdesivir to improve the outcome of patients hospitalized with COVID-19. Methods. We conducted a retrospective real-life study that included all patients from the early access program of remdesivir in France. The primary endpoint was the clinical course evolution of critically ill and hospitalized COVID-19 patients treated with remdesivir. Secondary endpoints were the SOFA score evolution within 29 days following the admission and mortality at 29 and 90 days. Results. Eighty-five patients were enrolled in 22 sites from January to April 2020. The median WHO and SOFA scores were respectively reduced by two and six points between days 1 and 29. Improvement in the WHO-CPS and the SOFA score were observed in 83.5% and 79.3% of patients, respectively, from day 10. However, there was no effect of remdesivir on the 90-day survival based on the control cohort for hospitalized COVID-19 patients with invasive ventilation. Conclusions. SOFA score appeared to be an attractive approach to assess remdesivir efficacy and stratify its utilization or not in critically ill patients with COVID-19. This study brings a new clinical benchmark for therapeutic decision making and supports the use of remdesivir for some hospitalized COVID-19 patients.
Fichier principal
Vignette du fichier
jcm-11-06545.pdf (2.23 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03985026 , version 1 (06-06-2023)

Licence

Paternité

Identifiants

Citer

Jeremie Zerbit, Marion Detroit, Sylvie Chevret, Frederic Pene, Charles-Edouard Luyt, et al.. Remdesivir for Patients Hospitalized with COVID-19 Severe Pneumonia: A National Cohort Study (Remdeco-19). Journal of Clinical Medicine, 2022, 11 (21), pp.6545. ⟨10.3390/jcm11216545⟩. ⟨hal-03985026⟩
75 Consultations
29 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More